REGENXBIO Inc.
RGNX
NASDAQ·Healthcare·Biotechnology·Mkt cap $462.2M
$8.94
▼ -2.83%
P/E
-2.36
Mkt Cap
$462.2M
52-Wk Range
$5.46–$16.19
52-Week Range
$5.46 - $16.19
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 5.7% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary NAV Technology Platform with broad applicability across multiple disease indications
- Lead product RGX-314 in Phase III trials for wet AMD, a large market opportunity
- Diversified pipeline spanning ophthalmology, neurology, and rare genetic diseases
- Revenue-generating licensing partnerships reducing development risk and funding needs
Bear Case
1 risk
- Average volatility.
Growth
Mild headwinds expected
Advancement of RGX-314 toward potential FDA approval and commercialization in wet AMD
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Hot
+45.8% over 3m
Quality
Strong
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying RGNX right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 5, 2026
AUG 6, 2026
Reported EPS of $0.43 vs $0.08 consensus (+446.2% surprise). Revenue of $108.0M vs $97.6M expected (+10.6%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+446.2%
Revenue trend · last 8Q
—
-4%
+470%
-4%
+23%
+43%
-93%
+406%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$24.2M
$21.2M
$89.0M
$21.4M
$29.7M
$30.3M
$6.4M
$108.0M
Margins · last 8Q
Gross
99.0%
Operating
27.1%
Profit
21.0%
Wall Street consensus
4 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: HC Wainwright · Aug 10, 2026
vs Industry
How RGNX stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related